Fast Five Quiz: Myelodysplastic Syndrome Management

Emmanuel C. Besa, MD


May 12, 2021

Allogeneic hematopoietic stem cell transplant tends to be reserved for patients younger than 60 years because of the poor tolerance older patients and those with comorbidities have for this treatment. The IPSS-R is used to estimate patients' survival and risk of progression to acute myelogenous leukemia. For young people with high-risk disease, the risks of transplant may be outweighed by the risk of disease progression. Thus, transplant is an option for younger patients with high-risk disease.

Low-risk MDS is when a patient has a low probability of progression to acute myelogenous leukemia, and transplant is generally not offered to these patients. Although use of reduced-intensity conditioning regimens are increasing the age at which transplant is considered, transplant therapy is generally most appropriate for younger patients.

Learn more about determining disease staging in MDS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: